Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
Massimo Di Maïo(University of Siena), Grazia Arpino(University of Naples Federico II), Francesco Schettini(Target (United States)), Fabio Puglisi(University of Udine), Claudia Bighin(Azienda Ospedaliera S.Maria), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Alessandra Fabi(Agostino Gemelli University Polyclinic), Mario Giuliano(Regione Campania), Tommaso Ruelle(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Laura Marandino, Caterina Picotto(A. O. Ordine Mauriziano di Torino), Ferdinando Riccardi(Fatebenefratelli Hospital)
Cited by 9
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830